{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:47:16Z","timestamp":1787647636499,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1038\/nrd1752","type":"journal-article","created":{"date-parts":[[2005,6,2]],"date-time":"2005-06-02T07:11:14Z","timestamp":1117696274000},"page":"510-518","source":"Crossref","is-referenced-by-count":265,"title":["Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab"],"prefix":"10.1038","volume":"4","author":[{"given":"Lawrence","family":"Steinman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrd1752_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/ni0901-762","volume":"2","author":"L Steinman","year":"2001","unstructured":"Steinman, L. Multiple sclerosis: a two-stage disease. Nature Immunol. 2, 762\u20135 (2001).","journal-title":"Nature Immunol."},{"key":"BFnrd1752_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1055\/s-2003-41138","volume":"23","author":"BC Kiesierer","year":"2003","unstructured":"Kiesierer, B. C. & Hartung, H. P. Current disease modifying therapies in mutlple sclerosis. Semin. Neurol. 23, 133\u2013146 (2003).","journal-title":"Semin. Neurol."},{"key":"BFnrd1752_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0896-6273(03)00326-X","volume":"38","author":"S Zamvil","year":"2003","unstructured":"Zamvil, S. & Steinman, L. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron 38, 685\u2013688 (2003).","journal-title":"Neuron"},{"key":"BFnrd1752_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nri1108","volume":"3","author":"L Steinman","year":"2003","unstructured":"Steinman, L. & Zamvil, S. Transcriptional analysis of targets in multiple sclerosis. Nature Rev. Immunol. 3, 483\u2013493 (2003).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrd1752_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nm0305-252","volume":"11","author":"M Platten","year":"2005","unstructured":"Platten, M. & Steinman, L. Multiple sclerosis: trapped in deadly glue. Nature Med. 11, 252\u2013253 (2005).","journal-title":"Nature Med."},{"key":"BFnrd1752_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"T Yednock","year":"1992","unstructured":"Yednock, T. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against \u03b14\u03b21 integrin. Nature 356, 63\u201366 (1992). The first description of the crucial role of \u03b14\u03b21 integrin in the homing of lymphocytes to inflamed brain. Antibodies to \u03b14\u03b21 integrin blocked paralysis in EAE.","journal-title":"Nature"},{"key":"BFnrd1752_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0092-8674(94)90337-9","volume":"76","author":"TA Springer","year":"1994","unstructured":"Springer, T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76, 301\u2013314 (1994). Excellent early review of the physiology of lymphocyte adhesion to inflamed endothelium.","journal-title":"Cell"},{"key":"BFnrd1752_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1126\/science.272.5258.60","volume":"272","author":"EC Butcher","year":"1996","unstructured":"Butcher, E. C. & Picker, L. J. Lymphocyte homing and homeostasis. Science 272, 60\u201366 (1996). Another excellent review of the physiology of lymphocyte adhesion to inflamed endothelium.","journal-title":"Science"},{"key":"BFnrd1752_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1056\/NEJM200010053431407","volume":"343","author":"UH von Adrian","year":"2000","unstructured":"von Adrian, U. H. & Mackay, C. R. T cell function and migration: two sides of the same coin. N. Engl. J. Med. 343, 1020\u20131024 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1752_CR10","doi-asserted-by":"publisher","first-page":"7111","DOI":"10.1073\/pnas.78.11.7111","volume":"78","author":"L Steinman","year":"1981","unstructured":"Steinman, L., Rosenbaum, J. T., Sriram, S. & McDevitt, H. O. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc. Natl Acad. Sci. USA 78, 7111\u20137114 (1981).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd1752_CR11","first-page":"345","volume":"54","author":"K Sakai","year":"1986","unstructured":"Sakai, K., Tabira, T., Endoh, M. & Steinman, L. Ia expression in chronic relapsing experimental allergic encephalomyelitis induced by long-term cultured T cell lines in mice. Lab. Invest. 54, 345\u2013352 (1986).","journal-title":"Lab. Invest."},{"key":"BFnrd1752_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0165-5728(83)90029-2","volume":"5","author":"L Steinman","year":"1983","unstructured":"Steinman, L., Solomon, D., Zamvil, S., Lim, M. & Sriram, S. Prevention of EAE with anti I-A antibody: Decreased accumulation of radiolabeled lymphocytes in the central nervous system. J. Neuroimmunol. 5, 91\u201397 (1983).","journal-title":"J. Neuroimmunol."},{"key":"BFnrd1752_CR13","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1084\/jem.158.4.1362","volume":"158","author":"S Sriram","year":"1983","unstructured":"Sriram, S. & Steinman, L. Anti I-A antibody suppresses active encephalomyelitis: treatment model for IR gene linked diseases. J. Exp. Med. 158, 1362\u20131367 (1983).","journal-title":"J. Exp. Med."},{"key":"BFnrd1752_CR14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1128\/JVI.61.3.898-903.1987","volume":"61","author":"A Friedmann","year":"1987","unstructured":"Friedmann, A., Frankel, G., Lorch, Y. & Steinman, L. Monoclonal anti I-A reverses chronic paralysis and demyelination in Theiler's virus infected mice: critical importance of timing of treatment. J. Virol. 61, 898\u2013903 (1987).","journal-title":"J. Virol."},{"key":"BFnrd1752_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/292060a0","volume":"292","author":"A Ben-Nun","year":"1981","unstructured":"Ben-Nun, A., Wekerle, H. & Cohen, I. R. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 292, 60\u201362 (1981).","journal-title":"Nature"},{"key":"BFnrd1752_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/317355a0","volume":"317","author":"S Zamvil","year":"1985","unstructured":"Zamvil, S. et al. T cell clones specific for myelin basic protein induce chronic relapsing EAE and demyelination. Nature 317, 355\u2013358 (1985).","journal-title":"Nature"},{"key":"BFnrd1752_CR17","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1084\/jem.144.3.828","volume":"144","author":"HB Stamper","year":"1976","unstructured":"Stamper, H. B. & Woodruff, J. J. Lymphocyte homing into lymph nodes: in vitro demonstration of the selective affinity of recirculating lymphocytes for high-endothelial venules. J. Exp. Med. 144, 828\u2013833 (1976).","journal-title":"J. Exp. Med."},{"key":"BFnrd1752_CR18","doi-asserted-by":"publisher","first-page":"6896","DOI":"10.1073\/pnas.96.12.6896","volume":"96","author":"S Brocke","year":"1999","unstructured":"Brocke, S., Piercy, C., Steinman, L., Weissman, I. L. & Veromaa, T. Antibodies to CD44 and integrin \u03b14, but not L-selectin, prevent CNS inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl Acad. Sci. USA 96, 6896\u20136901 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd1752_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1084\/jem.177.1.57","volume":"177","author":"JL Baron","year":"1993","unstructured":"Baron, J. L., Madri, J. A., Ruddle, N. H., Hashim, G. & Janeway, C. A. Jr. Surface expression of \u03b14 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177, 57\u201368 (1993).","journal-title":"J. Exp. Med."},{"key":"BFnrd1752_CR20","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.4049\/jimmunol.154.11.5876","volume":"154","author":"MM Verbeek","year":"1995","unstructured":"Verbeek, M. M., Westphal, J. R., Ruiter, D. J. & de Waal, R. M. T lymphocyte adhesion to human brain pericytes is mediated via very late antigen-4\/vascular cell adhesion molecule-1 interactions. J. Immunol. 154, 5876\u20135884 (1995).","journal-title":"J. Immunol."},{"key":"BFnrd1752_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-5728(94)00165-K","volume":"58","author":"SJ Kent","year":"1995","unstructured":"Kent, S. J. et al. A monoclonal antibody to \u03b14 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58, 1\u201310 (1995).","journal-title":"J. Neuroimmunol."},{"key":"BFnrd1752_CR22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1212\/WNL.47.4.1053","volume":"47","author":"E Keszthelyi","year":"1996","unstructured":"Keszthelyi, E. et al. Evidence for a prolonged role of \u03b14 integrin throughout active experimental allergic encephalomyelitis. Neurology 47, 1053\u20131059 (1996).","journal-title":"Neurology"},{"key":"BFnrd1752_CR23","doi-asserted-by":"publisher","first-page":"10494","DOI":"10.1073\/pnas.90.22.10494","volume":"90","author":"X Yang","year":"1993","unstructured":"Yang, X., Karin, N., Tisch, R., Steinman, L. & McDevitt, H. O. Inhibition of insulitis and prevention of diabetes in NOD mice by blocking L-selectin and VLA-4 adhesion receptors. Proc. Natl Acad. Sci. USA 90, 10494\u201310498 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd1752_CR24","doi-asserted-by":"publisher","first-page":"12604","DOI":"10.1073\/pnas.91.26.12604","volume":"91","author":"X Yang","year":"1994","unstructured":"Yang, X. et al. A predominant role of \u03b14-integrin in the spontaneous development of autoimmune diabetes in NOD Mice. Proc. Natl Acad. Sci. USA 91, 12604\u201312608 (1994). Demonstrated that \u03b14-integrin is important in homing to inflamed pancreas in a model of type 1 diabetes.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd1752_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0165-5728(97)00249-X","volume":"84","author":"SA Rubin","year":"1998","unstructured":"Rubin, S. A., Yednock, T. A. & Carbone, K. M. In vivo treatment with anti-\u03b14 integrin suppresses clinical and pathological evidence of Borna disease virus infection. J. Neuroimmunol. 84, 158\u2013163 (1998).","journal-title":"J. Neuroimmunol."},{"key":"BFnrd1752_CR26","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1212\/WNL.52.5.1072","volume":"52","author":"WA Sheremata","year":"1999","unstructured":"Sheremata, W. A., Vollmer, T. L., Stone, L. A., Willmer-Hulme, A. J. & Koller, M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52, 1072\u20131074 (1999).","journal-title":"Neurology"},{"key":"BFnrd1752_CR27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1172\/JCI11717","volume":"107","author":"BE Theien","year":"2001","unstructured":"Theien, B. E. et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 107, 995\u20131006 (2001). Worsening of EAE is described after administration of \u03b14-integrin antibody.","journal-title":"J. Clin. Invest."},{"key":"BFnrd1752_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/HAB-1997-8102","volume":"8","author":"JP Leger","year":"1997","unstructured":"Leger, J. P. et al. Humanisation of a mouse antibody against human \u03b1-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum. Antibodies 8, 3\u201316 (1997).","journal-title":"Hum. Antibodies"},{"key":"BFnrd1752_CR29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1212\/WNL.53.3.466","volume":"53","author":"N Tubridy","year":"1999","unstructured":"Tubridy, N. et al. The effect of anti-a4 integrin antibody on brain lesion activity in MS. Neurology 53, 466\u2013472 (1999).","journal-title":"Neurology"},{"key":"BFnrd1752_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMoa020696","volume":"348","author":"DA Miller","year":"2003","unstructured":"Miller, D. A. et al. A controlled trial of natalizumab for relapsing-remitting multiple sclerosis. N. Engl. J. Med. 348, 15\u201323 (2003). Phase II trial results show reduction in clinical relapses during a 6-month course of natalizumab.","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1752_CR31","unstructured":"US FDA. Natalizumab (marketed as Tysabri) Information [online], < http:\/\/www.fda.gov\/cder\/drug\/infopage\/natalizumab\/default.htm > (2005). FDA website with the results of the Phase III clinical trials leading to the approval of natalizumab. This page also contains the labelling of the approved drug, and the notice of the voluntary withdrawal of the drug."},{"key":"BFnrd1752_CR32","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1128\/JVI.77.7.3913-3921.2003","volume":"77","author":"M Caruso","year":"2003","unstructured":"Caruso, M., Belloni, L., Sthandier, O., Amati, P. & Garcia, M. \u03b14\u03b21 integrin acts as a cell receptor for murine polyomavirus at the postattachment level. J. Virol. 77, 3913\u20133921 (2003).","journal-title":"J. Virol."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd1752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd1752","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd1752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:49:35Z","timestamp":1684453775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd1752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["BFnrd1752"],"URL":"https:\/\/doi.org\/10.1038\/nrd1752","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}